List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9429330/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Birmingham Vasculitis Activity Score und der Short Form 36-Item Health Survey als PrÄ d iktoren aktueller depressiver StĶrungen bei Patienten mit antineutrophile-zytoplasmatische-AntikĶrper-assoziierter Vaskulitis wÄ ¤ rend der SARS-CoV-2-Pandemie. Zeitschrift Fur Rheumatologie. 2024. 83. 222-229.	1.0	1
2	Reclassification of previously diagnosed GPA patients using the 2022 ACR/EULAR classification criteria. Rheumatology, 2023, 62, 1179-1186.	1.9	8
3	2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease by Wallace <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e179-e179.	0.9	10
4	Increased prevalence rate of metabolic syndrome is an independent predictor of cardiovascular disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Rheumatology International, 2022, 42, 291-302.	3.0	7
5	Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome. Rheumatology, 2022, 61, 1548-1555.	1.9	6
6	Nutrition Risk Index Score at Diagnosis Can Effectively Predict Poor Prognosis in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. , 2022, 32, 423-431.		4
7	Drug Survival of Biologic Therapy in Elderly Patients With Rheumatoid Arthritis Compared With Nonelderly Patients. Journal of Clinical Rheumatology, 2022, 28, e81-e88.	0.9	4
8	GeTe Nanosheets as Theranostic Agents for Multimodal Imaging and Therapy of Inflammatory Bowel Disease. Advanced Functional Materials, 2022, 32, 2107433.	14.9	7
9	A retrospective analysis of antineutrophil cytoplasmic antibody-associated vasculitis aiming for an equation prediction end-stage renal disease. Clinical Rheumatology, 2022, 41, 773-781.	2.2	5
10	Association Between Idiopathic Cutaneous Leukocytoclastic Angiitis and ANCA-negative Microscopic Polyangiitis. Journal of Rheumatic Diseases, 2022, 29, 40-45.	1.1	0
11	Clinical application of low erythrocyte sedimentation rate/high Câ€reactive protein to antineutrophil cytoplasmic antibodyâ€associated vasculitis. Journal of Clinical Laboratory Analysis, 2022, 36, e24237.	2.1	2
12	Aortic valve surgery in patients with Takayasu's arteritis: a nationwide analysis of 1,197 patients during a 9-year period. Clinical and Experimental Rheumatology, 2022, 40, 568-574.	0.8	0
13	New body mass index for predicting prognosis in patients with antineutrophil cytoplasmic antibodyâ€associated vasculitis. Journal of Clinical Laboratory Analysis, 2022, , e24357.	2.1	4
14	Clinical Features of Anti-Synthetase Syndrome Associated with Prognosis in Patients with Dermatomyositis and Polymyositis. Journal of Clinical Medicine, 2022, 11, 2052.	2.4	2
15	Incidence, prevalence and risk of stroke in patients with Takayasu arteritis: a nationwide population-based study in South Korea. Stroke and Vascular Neurology, 2022, 7, 149-157.	3.3	7
16	Anti-Citrullinated Peptide Antibody Expression and Its Association with Clinical Features and Outcomes in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Medicina (Lithuania), 2022, 58, 558.	2.0	2
17	Effect of numbers of metabolic syndrome components on mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis with metabolic syndrome Clinical and Experimental Rheumatology, 2022, , .	0.8	0
18	Incidence and Patterns of Interstitial Lung Disease and Their Clinical Impact on Mortality in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Korean Single-Centre Observational Study. Journal of Immunology Research, 2022, 2022, 1-7.	2.2	3

#	Article	IF	CITATIONS
19	Triglyceride and Glucose Index Predicts Acute Coronary Syndrome in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Diagnostics, 2022, 12, 1486.	2.6	3
20	Modified Body Mass Index at Diagnosis is a Useful Predictor of Mortality in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatic Diseases, 2022, 29, 154-161.	1.1	0
21	Clinical Significance of Antineutrophil Cytoplasmic Antibody Positivity in Patients Infected with SARS-CoV-2. Journal of Clinical Medicine, 2022, 11, 4152.	2.4	3
22	Serum albumin, prealbumin, and ischemia-modified albumin levels in patients with ANCA-associated vasculitis: A prospective cohort study. PLoS ONE, 2022, 17, e0271055.	2.5	5
23	Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2021, 80, 632-640.	0.9	103
24	Clinical and imaging findings suggestive of histopathological immunoglobulin G4-related disease: a single-center retrospective study. Clinical Rheumatology, 2021, 40, 1423-1430.	2.2	2
25	LBEC0101, an etanercept biosimilar for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2021, 21, 1-8.	3.1	1
26	Serological Biomarkers and Indices for the Current Activity and Prognosis of ANCA-Associated Vasculitis: Experience in a Single Centre in Korea. Yonsei Medical Journal, 2021, 62, 279.	2.2	8
27	Editorial Commentary: Stem Cell Treatment in Knee Osteoarthritis: What for? Pain Management or Cartilage Regeneration?. Arthroscopy - Journal of Arthroscopic and Related Surgery, 2021, 37, 359-361.	2.7	1
28	Systemic inflammation response index predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. International Urology and Nephrology, 2021, 53, 1631-1638.	1.4	4
29	Association Between Serum Alarmin Levels and Disease-specific Indices in Patients With Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis. In Vivo, 2021, 35, 1761-1768.	1.3	1
30	A clinical comparison of an endothelin receptor antagonist and phosphodiesterase type 5 inhibitors for treating digital ulcers of systemic sclerosis. Rheumatology, 2021, 60, 5814-5819.	1.9	5
31	Fucoxanthin Suppresses Osteoclastogenesis via Modulation of MAP Kinase and Nrf2 Signaling. Marine Drugs, 2021, 19, 132.	4.6	20
32	Fibrosis-5 predicts end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis without substantial liver diseases. Clinical and Experimental Medicine, 2021, 21, 399-406.	3.6	4
33	Fibrinogen to albumin ratio reflects the activity of antineutrophil cytoplasmic antibodyâ€essociated vasculitis. Journal of Clinical Laboratory Analysis, 2021, 35, e23731.	2.1	7
34	Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study. Arthritis Research and Therapy, 2021, 23, 77.	3.5	8
35	Correlation between serum cysteine-rich protein 61 and disease activity of antineutrophil cytoplasmic antibody–associated vasculitis. Clinical Rheumatology, 2021, 40, 3703-3710.	2.2	1
36	Risk of Stroke in Systemic Necrotizing Vasculitis: A Nationwide Study Using the National Claims Database. Frontiers in Immunology, 2021, 12, 629902.	4.8	8

#	Article	IF	CITATIONS
37	Reclassification of Korean patients with polymyositis and dermatomyositis based on the Bohan and Peter criteria by the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies. Korean Journal of Internal Medicine, 2021, 36, 441-446.	1.7	3
38	Unclassifiable repeated antineutrophil cytoplasmic antibody (ANCA) positivity in diseases other than ANCA-associated vasculitis. Zeitschrift Fur Rheumatologie, 2021, , 1.	1.0	4
39	Association between follistatin-related protein 1 and the functional status of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Chinese Medical Journal, 2021, 134, 1168-1174.	2.3	0
40	Total Haemolytic Complement Activity at Diagnosis as an Indicator of the Baseline Activity of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatic Diseases, 2021, 28, 85-93.	1.1	1
41	Clinical features of Korean elderly patients with antineutrophil cytoplasmic antibody-associated vasculitis. Korean Journal of Internal Medicine, 2021, 36, 731-741.	1.7	3
42	Novel mortalityâ€predicting index at diagnosis can effectively predict allâ€cause mortality in patients with antineutrophil cytoplasmic antibodyâ€associated vasculitis. Journal of Clinical Laboratory Analysis, 2021, 35, e23885.	2.1	4
43	Comparison of Retention Rates Between Tumor Necrosis Factor-α Inhibitors in Patients With Ankylosing Spondylitis: Data From the Korean College of Rheumatology Biologics Registry. Frontiers in Medicine, 2021, 8, 689609.	2.6	6
44	Clinical significance of large unstained cell count in estimating the current activity of antineutrophil cytoplasmic antibodyâ€associated vasculitis. International Journal of Clinical Practice, 2021, 75, e14512.	1.7	3
45	Predictive Ability of Serum IL-27 Level for Assessing Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Mediators of Inflammation, 2021, 2021, 1-8.	3.0	2
46	Serum adipokine profiles in patients with microscopic polyangiitis and granulomatosis with polyangiitis: An exploratory analysis. PLoS ONE, 2021, 16, e0254226.	2.5	1
47	Evaluation of body composition using computed tomography in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Korean Journal of Internal Medicine, 2021, 36, 1221-1232.	1.7	1
48	The novel fibrosis index at diagnosis may predict all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis without substantial liver diseases. Clinics, 2021, 76, e2501.	1.5	2
49	Antineutrophil Cytoplasmic Antibody Positivity Is Associated with Vascular Involvement in Behçet's Disease. Yonsei Medical Journal, 2021, 62, 149.	2.2	6
50	Male Sex Is a Significant Predictor of All-cause Mortality in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Korean Medical Science, 2021, 36, e120.	2.5	8
51	The Efficacy of Mycophenolate Mofetil in Remission Maintenance Therapy for Microscopic Polyangiitis and Granulomatosis with Polyangiitis. Yonsei Medical Journal, 2021, 62, 494.	2.2	2
52	Efficacy of the fibrosis index for predicting endâ€stage renal disease in patients with antineutrophil cytoplasmic antibodyâ€associated vasculitis. International Journal of Clinical Practice, 2021, 75, e13929.	1.7	4
53	Serum Clusterin Level Could Reflect the Current Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Yonsei Medical Journal, 2021, 62, 1016.	2.2	3
54	Serum progranulin as a predictive marker for high activity of antineutrophil cytoplasmic antibodyâ€associated vasculitis. Journal of Clinical Laboratory Analysis, 2021, 35, e24048.	2.1	1

#	Article	IF	CITATIONS
55	Prevalence of Osteopenia in Drug-Naive Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Journal of Clinical Rheumatology, 2021, 27, e330-e335.	0.9	2
56	A new index for distinguishing hypereosinophilic syndrome and antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis. Asian Pacific Journal of Allergy and Immunology, 2021, , .	0.4	3
57	Serum granzyme B is associated with otorhinolaryngological, pulmonary, and renal involvement of antineutrophil cytoplasmic antibody-associated vasculitis. Journal of Investigative Medicine, 2021, 69, 91-95.	1.6	Ο
58	Pan-immune-inflammation value at diagnosis independently predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 88-93.	0.8	1
59	D-dimer predicts poor hospitalisation outcomes in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 94-100.	0.8	Ο
60	Aortic valve surgery in patients with Takayasu's arteritis: a nationwide analysis of 1,197 patients during a 9-year period. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
61	Serum galectin-9 could be a potential biomarker in assessing the disease activity of antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
62	Significance of antineutrophil cytoplasmic antibody positivity in patients with systemic sclerosis: a single-centre pilot study in Korea. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 111-118.	0.8	0
63	Is thyroid autoimmunity a predisposing factor for fibromyalgia? A systematic review and meta-analysis. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
64	D-dimer predicts poor hospitalisation outcomes in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 94-100.	0.8	3
65	Pan-immune-inflammation value at diagnosis independently predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Rheumatology, 2021, 39, 88-93.	0.8	14
66	Significance of antineutrophil cytoplasmic antibody positivity in patients with systemic sclerosis: a single-centre pilot study in Korea. Clinical and Experimental Rheumatology, 2021, 39, 111-118.	0.8	0
67	Transcriptional Interactomic Inhibition of RORα Suppresses Th17-Related Inflammation. Journal of Inflammation Research, 2021, Volume 14, 7091-7105.	3.5	1
68	Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis. Korean Journal of Internal Medicine, 2021, , .	1.7	0
69	Clinical impact of proteinase 3-antineutrophil cytoplasmic antibody positivity in eosinophilic granulomatosis with polyangiitis. Korean Journal of Internal Medicine, 2021, , .	1.7	1
70	Metabolic Syndrome Severity Score, Comparable to Serum Creatinine, Could Predict the Occurrence of End-Stage Kidney Disease in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Journal of Clinical Medicine, 2021, 10, 5744.	2.4	5
71	Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study. Modern Rheumatology, 2020, 30, 70-77.	1.8	17
72	Multivariable index for assessing the activity and predicting allâ€cause mortality in antineutrophil cytoplasmic antibodyâ€associated vasculitis. Journal of Clinical Laboratory Analysis, 2020, 34, e23022.	2.1	13

#	Article	IF	CITATIONS
73	Can antineutrophil cytoplasmic antibody positivity at diagnosis predict the poor outcomes of Sjögren's syndrome?. Rheumatology International, 2020, 40, 1063-1070.	3.0	4
74	Clinical implication of chronic paranasal sinusitis for the classification of microscopic polyangiitis. International Journal of Clinical Practice, 2020, 74, e13431.	1.7	2
75	Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry. BioDrugs, 2020, 34, 89-98.	4.6	13
76	Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study. Clinical Rheumatology, 2020, 39, 831-840.	2.2	2
77	Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Biologics Registry. BioDrugs, 2020, 34, 529-539.	4.6	7
78	Punicalagin Ameliorates Lupus Nephritis via Inhibition of PAR2. International Journal of Molecular Sciences, 2020, 21, 4975.	4.1	14
79	Incidence of Tuberculosis in Systemic Necrotizing Vasculitides: A Population-Based Study From an Intermediate-Burden Country. Frontiers in Medicine, 2020, 7, 550004.	2.6	0
80	Disease-specific factors associated with cardiovascular events in patients with Takayasu arteritis. Arthritis Research and Therapy, 2020, 22, 180.	3.5	9
81	Atherogenic index of plasma predicts cerebrovascular accident occurrence in antineutrophil cytoplasmic antibody-associated vasculitis. Lipids in Health and Disease, 2020, 19, 184.	3.0	7
82	Serum Amyloid A Is a Biomarker of Disease Activity and Health-Related Quality-of-Life in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Disease Markers, 2020, 2020, 1-9.	1.3	4
83	Definite IgG4-related disease had no overlap with eosinophilic granulomatosis with polyangiitis in Korean patients: a pilot study in one centre. Clinical Rheumatology, 2020, 39, 3009-3015.	2.2	3
84	Association between the antineutrophil cytoplasmic antibody and late coronary arterial occlusive disease in patients with Takayasu arteritis. Journal of Cardiology, 2020, 76, 407-412.	1.9	3
85	Clinical implication of plasma exchange on life-threatening antineutrophil cytoplasmic antibody-associated vasculitis. BMC Pulmonary Medicine, 2020, 20, 147.	2.0	2
86	Clinical characteristics and long-term outcomes of Libman–Sacks endocarditis in patients with systemic lupus erythematosus. Lupus, 2020, 29, 1115-1120.	1.6	11
87	Methotrexate-loaded multifunctional nanoparticles with near-infrared irradiation for the treatment of rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 146.	3.5	29
88	Non-histologic factors discriminating proliferative lupus nephritis from membranous lupus nephritis. Arthritis Research and Therapy, 2020, 22, 138.	3.5	5
89	Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis. BMC Nephrology, 2020, 21, 258.	1.8	5
90	Hyperuricemia is associated with decreased renal function and occurrence of end-stage renal disease in patients with microscopic polyangiitis and granulomatosis with polyangiitis: a retrospective study. Rheumatology International, 2020, 40, 1089-1099.	3.0	7

#	Article	IF	CITATIONS
91	Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA). Seminars in Arthritis and Rheumatism, 2020, 50, 1414-1420.	3.4	3
92	Serum interleukin-16 significantly correlates with the Vasculitis Damage Index in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Research and Therapy, 2020, 22, 73.	3.5	6
93	Serum Mannose-Binding Lectin Levels Are Correlated with the Disease Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Single-Center Study. Tohoku Journal of Experimental Medicine, 2020, 251, 117-123.	1.2	7
94	Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies. Journal of Korean Medical Science, 2020, 35, e335.	2.5	4
95	Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis. Yonsei Medical Journal, 2020, 61, 951.	2.2	4
96	Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator. Yonsei Medical Journal, 2020, 61, 712.	2.2	5
97	Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor 1 Is Inversely Correlated with the Activity of ANCA-Associated Vasculitis. Yonsei Medical Journal, 2020, 61, 720.	2.2	2
98	Lipid Profiles in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Cross-sectional Analysis. Journal of Rheumatic Diseases, 2020, 27, 261-269.	1.1	4
99	Novel PAR2 antagonist ameliorates progression of lupus nephritis in NZB/Z F1 mice. FASEB Journal, 2020, 34, 1-1.	0.5	0
100	Pregnancy Morbidities in Korean Patients with Takayasu Arteritis: A Monocentric Pilot Study. Yonsei Medical Journal, 2020, 61, 970.	2.2	3
101	MiR-451 suppresses inflammatory responses in ankylosing spondylitis by targeting macrophage migration inhibitory factor. Clinical and Experimental Rheumatology, 2020, 38, 275-281.	0.8	4
102	Retention rate and long-term safety of biosimilar CT-P13 in patients with ankylosing spondylitis: data from the Korean College of Rheumatology Biologics registry. Clinical and Experimental Rheumatology, 2020, 38, 267-274.	0.8	6
103	Will the HALP score help to assess the activity and predict the prognosis of antineutrophil cytoplasmic antibody-associated vasculitis?. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 236-237.	0.8	2
104	Application of the 2019 classification criteria for systemic lupus erythematosus to patients with established ANCA-associated vasculitis. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 243-244.	0.8	0
105	Clinical significance of ANCA positivity in patients with IgA vasculitis: a retrospective monocentric study. Rheumatology International, 2019, 39, 1927-1936.	3.0	4
106	Atializumab, a humanized anti-aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1) antibody significantly improves nephritis in (NZB/NZW) F1 mice. Biomaterials, 2019, 220, 119408.	11.4	7
107	Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clinical Rheumatology, 2019, 38, 3485-3491.	2.2	7
108	Evaluation of macrophage activation syndrome in hospitalised patients with Kikuchi-Fujimoto disease based on the 2016 EULAR/ACR/PRINTO classification criteria. PLoS ONE, 2019, 14, e0219970.	2.5	8

#	Article	IF	CITATIONS
109	Could hypereosinophilia at diagnosis estimate the current activity or predict relapse in systemic immunosuppressive drug-naÃ ⁻ ve patients with eosinophilic granulomatosis with polyangiitis?. Rheumatology International, 2019, 39, 1899-1905.	3.0	3
110	Causal effect of alcohol consumption on hyperuricemia using a Mendelian randomization design. International Journal of Rheumatic Diseases, 2019, 22, 1912-1919.	1.9	23
111	Serum Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein-1 Can Predict Severe Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Pilot Monocentric Study. BioMed Research International, 2019, 2019, 1-6.	1.9	7
112	Comparison of the Clinical Implications among Five Different Nutritional Indices in Patients with Lupus Nephritis. Nutrients, 2019, 11, 1456.	4.1	14
113	Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study. Arthritis Research and Therapy, 2019, 21, 163.	3.5	16
114	Risk of Cancers in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from the Korea National Health Insurance Claims Database 2010–2018. Journal of Clinical Medicine, 2019, 8, 1871.	2.4	10
115	Clinical characteristics of patients with systemic lupus erythematosus showing a false-positive result of syphilis screening. Rheumatology International, 2019, 39, 1859-1866.	3.0	4
116	Classification of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatic Diseases, 2019, 26, 156.	1.1	11
117	Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatology International, 2019, 39, 1937-1944.	3.0	26
118	Fibrosis-4 index at diagnosis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis. BMC Gastroenterology, 2019, 19, 90.	2.0	13
119	Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. Arthritis Research and Therapy, 2019, 21, 122.	3.5	12
120	Anti-phospholipid antibody syndrome occurrence in patients with persistent anti-phospholipid antibodies. Rheumatology International, 2019, 39, 1359-1367.	3.0	4
121	Thyroid Dysfunction in Patients with Antineutrophil Cytoplasmic Antibody–associated Vasculitis: A Monocentric Retrospective Study. Journal of Rheumatology, 2019, 46, 1248-1250.	2.0	2
122	Comparison of Radiological and Histological Findings of Lung Parenchyma in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Yonsei Medical Journal, 2019, 60, 454.	2.2	10
123	Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians. PLoS Genetics, 2019, 15, e1008092.	3.5	36
124	Should nasal biopsy inevitably be performed for classifying granulomatosis with polyangiitis in patients with rhinosinusitis? A retrospective chart review study. Rheumatology International, 2019, 39, 885-892.	3.0	3
125	ExÂVivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma. Clinical Lung Cancer, 2019, 20, e299-e308.	2.6	2
126	Serum interleukin-21 positivity could indicate the current activity of antineutrophil cytoplasmic antibody-associated vasculitis: a monocentric prospective study. Clinical Rheumatology, 2019, 38, 1685-1690.	2.2	5

#	Article	IF	CITATIONS
127	Prognostic nutritional index is associated with disease severity and relapse in ANCAâ€associated vasculitis. International Journal of Rheumatic Diseases, 2019, 22, 797-804.	1.9	16
128	ANCA positivity at the time of renal biopsy is associated with chronicity index of lupus nephritis. Rheumatology International, 2019, 39, 879-884.	3.0	9
129	Persistent antiphospholipid antibodies are associated with thrombotic events in ANCA-associated vasculitis: A retrospective monocentric study. Nefrologia, 2019, 39, 395-401.	0.4	6
130	Clinical role of albumin to globulin ratio in microscopic polyangiitis: a retrospective monocentric study. Clinical Rheumatology, 2019, 38, 487-494.	2.2	11
131	Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis. Clinical and Experimental Nephrology, 2019, 23, 223-230.	1.6	20
132	Systemic immuneâ€inflammation index could estimate the crossâ€sectional high activity and the poor outcomes in immunosuppressive drugâ€naÃīve patients with antineutrophil cytoplasmic antibodyâ€associated vasculitis. Nephrology, 2019, 24, 711-717.	1.6	42
133	No overlap between IgC4-related disease and microscopic polyangiitis and granulomatosis with polyangiitis despite elevated serum IgG4 at diagnosis: a retrospective monocentric study. Clinical Rheumatology, 2019, 38, 1147-1154.	2.2	21
134	Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative Review. Yonsei Medical Journal, 2019, 60, 10.	2.2	27
135	Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2019, 22, 96-102.	1.9	6
136	Controlling Nutritional Status Score is Associated with All-Cause Mortality in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Yonsei Medical Journal, 2019, 60, 1164.	2.2	8
137	Eosinophilic Granulomatosis with Polyangiitis: Experiences in Korean Patients. Yonsei Medical Journal, 2019, 60, 705.	2.2	11
138	Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data. Korean Journal of Internal Medicine, 2019, 34, 669-677.	1.7	13
139	Subclinical but significant liver fibrosis in patients with ANCA-associated vasculitis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 26-31.	0.8	1
140	Serum soluble programmed cell death protein 1 could predict the current activity and severity of antineutrophil cytoplasmic antibody-associated vasculitis: a monocentric prospective study. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 116-121.	0.8	2
141	Intranuclear delivery of the transcription modulation domain of Tbet-improved lupus nephritis in (NZB/NZW) F1 lupus-prone mice. Kidney International, 2018, 93, 1118-1130.	5.2	9
142	Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. Clinical Rheumatology, 2018, 37, 2133-2141.	2.2	12
143	Mean platelet volume can estimate the current vasculitis activity of microscopic polyangiitis. Rheumatology International, 2018, 38, 1095-1101.	3.0	9
144	Increased serum interleukinâ€32 levels in patients with Behçet's disease. International Journal of Rheumatic Diseases, 2018, 21, 2167-2174.	1.9	20

#	Article	IF	CITATIONS
145	Decreased muscle mass is independently associated with knee pain in female patients with radiographically mild osteoarthritis: a nationwide cross-sectional study (KNHANES 2010–2011). Clinical Rheumatology, 2018, 37, 1333-1340.	2.2	15
146	Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor. Clinical Rheumatology, 2018, 37, 2771-2779.	2.2	10
147	The Expression of Immunomodulation-Related Cytokines and Genes of Adipose- and Bone Marrow-Derived Human Mesenchymal Stromal Cells from Early to Late Passages. Tissue Engineering and Regenerative Medicine, 2018, 15, 771-779.	3.7	20
148	Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide KOrean College of Rheumatology BIOlogics (KOBIO) registry. PLoS ONE, 2018, 13, e0205651.	2.5	13
149	Application of 2012 EULAR/ACR criteria for polymyalgia rheumatica to Korean patients previously classified by Chuang and Hunder criteria or Healey criteria. International Journal of Rheumatic Diseases, 2018, 21, 1838-1843.	1.9	2
150	HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. Rheumatology International, 2018, 38, 1531-1538.	3.0	5
151	Red Blood Cell Distribution Width Can Predict Vasculitis Activity and Poor Prognosis in Granulomatosis with Polyangiitis. Yonsei Medical Journal, 2018, 59, 294.	2.2	6
152	Neutrophil to lymphocyte ratio at diagnosis can estimate vasculitis activity and poor prognosis in patients with ANCA-associated vasculitis: a retrospective study. BMC Nephrology, 2018, 19, 187.	1.8	32
153	Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience. Yonsei Medical Journal, 2018, 59, 452.	2.2	27
154	Delta Neutrophil Index Is Associated with Vasculitis Activity and Risk of Relapse in ANCA-Associated Vasculitis. Yonsei Medical Journal, 2018, 59, 397.	2.2	16
155	Extravascular manifestations of Takayasu arteritis: focusing on the features shared with spondyloarthritis. Arthritis Research and Therapy, 2018, 20, 142.	3.5	20
156	Platelet to lymphocyte ratio is associated with the current activity of ANCA-associated vasculitis at diagnosis: a retrospective monocentric study. Rheumatology International, 2018, 38, 1865-1871.	3.0	28
157	C-Reactive Protein to Serum Albumin Ratio Is an Independent Predictor of All-Cause Mortality in Patients with ANCA-Associated Vasculitis. Yonsei Medical Journal, 2018, 59, 865.	2.2	36
158	Serum leucine-rich α2-glycoprotein is elevated in patients with systemic lupus erythematosus and correlates with disease activity. Clinica Chimica Acta, 2018, 486, 253-258.	1.1	10
159	Intraperitoneal infusion of mesenchymal stem cell attenuates severity of collagen antibody induced arthritis. PLoS ONE, 2018, 13, e0198740.	2.5	25
160	Red blood cell distribution width is useful in discriminating adult onset Still's disease and sepsis within 24 hours after hospitalization. Korean Journal of Internal Medicine, 2018, 33, 1234-1240.	1.7	8
161	Reclassification of polyarteritis nodosa based on the 1990 ACR criteria using the 2007 EMA algorithm modified by the 2012 CHCC definitions. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 165-166.	0.8	2
162	The utility of the ACR/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 85-87.	0.8	14

#	Article	IF	CITATIONS
163	Renal outcome of kidney-transplantation in Korean recipients with ANCA-associated vasculitis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 115-120.	0.8	2
164	Serum aminoacyl-tRNA synthetase-interacting multifunctional protein-1 (AIMP1), a novel disease activity predictive biomarker of systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2018, 36, 533-539.	0.8	2
165	Cancer development in Korean patients with ANCA-associated vasculitis: a single centre study. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 73-77.	0.8	3
166	The initial predictors of death in 153 patients with ANCA-associated vasculitis in a single Korean centre. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 65-72.	0.8	9
167	A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Annals of the Rheumatic Diseases, 2017, 76, 65-71.	0.9	39
168	Glycated albumin increases with disease activity in rheumatoid factor positive rheumatoid arthritis patients with normal fasting glucose and HbA1c. Joint Bone Spine, 2017, 84, 115-118.	1.6	5
169	Serum anti-lysozyme is associated with disease activity of Behçet's disease. International Journal of Rheumatic Diseases, 2017, 20, 261-268.	1.9	8
170	Five factor score of more than 1 is associated with relapse during the first 2 yearâ€follow up in patients with eosinophilic granulomatosis with polyangiitis. International Journal of Rheumatic Diseases, 2017, 20, 1261-1268.	1.9	12
171	Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry. Clinical Rheumatology, 2017, 36, 1013-1022.	2.2	20
172	In-hospital mortality in febrile lupus patients based on 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome. Seminars in Arthritis and Rheumatism, 2017, 47, 216-221.	3.4	28
173	Evaluation of Spleen Glucose Metabolism Using ¹⁸ F-FDG PET/CT in Patients with Febrile Autoimmune Disease. Journal of Nuclear Medicine, 2017, 58, 507-513.	5.0	33
174	Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial. Clinical Therapeutics, 2017, 39, 268-278.e2.	2.5	27
175	Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease. Journal of Rheumatology, 2017, 44, 996-1003.	2.0	43
176	Delta neutrophil index contributes to the differential diagnosis between acute gout attack and cellulitis within 24 hours after hospitalization. Rheumatology, 2017, 56, kew471.	1.9	11
177	Malignancies in Korean patients with immunoglobulin G4â€related disease. International Journal of Rheumatic Diseases, 2017, 20, 1028-1035.	1.9	35
178	Control of dental-derived induced pluripotent stem cells through modified surfaces for dental application. Acta Odontologica Scandinavica, 2017, 75, 309-318.	1.6	3
179	Birmingham vasculitis activity score at diagnosis is a significant predictor of relapse of polyarteritis nodosa. Rheumatology International, 2017, 37, 685-694.	3.0	11
180	Echocardiographic features in patients with ANCA-associated vasculitis within 3Âmonths before and after diagnosis. Clinical Rheumatology, 2017, 36, 2751-2759.	2.2	9

#	Article	IF	CITATIONS
181	Birmingham vasculitis activity score of more than 9.5 at diagnosis is an independent predictor of refractory disease in granulomatosis with polyangiitis. International Journal of Rheumatic Diseases, 2017, 20, 1593-1605.	1.9	17
182	Defective autophagy activity and its association with spinal damage in patients with ankylosing spondylitis. Joint Bone Spine, 2017, 84, 583-587.	1.6	12
183	Survival and prognostic factors in patients with connective tissue diseaseâ€associated pulmonary hypertension diagnosed by echocardiography: results from a Korean nationwide registry. International Journal of Rheumatic Diseases, 2017, 20, 1227-1236.	1.9	24
184	Fever as an initial manifestation of spondyloarthritis: A retrospective study. PLoS ONE, 2017, 12, e0184323.	2.5	5
185	Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus. Arthritis Research and Therapy, 2017, 19, 193.	3.5	14
186	Autologous Haematopoietic Stem Cell Transplantation for Refractory Rheumatic Diseases. Journal of Rheumatic Diseases, 2017, 24, 171.	1.1	0
187	Subsequent Thrombotic Outcomes in Patients with Ischemic Stroke with Antiphospholipid Antibody Positivity. Yonsei Medical Journal, 2017, 58, 1128.	2.2	6
188	Predictors of mortality in autoimmune disease patients with concurrent cytomegalovirus infections detected by quantitative real-time PCR. PLoS ONE, 2017, 12, e0181590.	2.5	9
189	Chest and renal involvements, Birmingham vascular activity score more than 13.5 and five factor score (1996) more than 1 at diagnosis are significant predictors of relapse of microscopic polyangiitis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 47-54.	0.8	11
190	Differential expressions of NOD-like receptors and their associations with inflammatory responses in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 630-637.	0.8	18
191	Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 111-118.	0.8	16
192	Gastrointestinal Risk Factors and Non-steroidal Anti-inflammatory Drugs Use in Rheumatoid Arthritis and Osteoarthritis Patients in Korea. Journal of Rheumatic Diseases, 2016, 23, 47.	1.1	2
193	Anti‧m is associated with the early poor outcome of lupus nephritis. International Journal of Rheumatic Diseases, 2016, 19, 897-902.	1.9	22
194	Clinical predictors of silent but substantial liver fibrosis in primary Sjogren's syndrome. Modern Rheumatology, 2016, 26, 576-582.	1.8	6
195	High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry. Nature Genetics, 2016, 48, 323-330.	21.4	219
196	Clinical features of psoriatic arthritis in Korean patients with psoriasis: a cross-sectional observational study of 196 patients with psoriasis using psoriatic arthritis screening questionnaires. Rheumatology International, 2016, 36, 207-212.	3.0	27
197	Real-time monitoring of 3D cell culture using a 3D capacitance biosensor. Biosensors and Bioelectronics, 2016, 77, 56-61.	10.1	53
198	Brain meningioma in a patient with systemic lupus erythematosus. Yeungnam University Journal of Medicine, 2016, 33, 159.	1.4	1

#	Article	IF	CITATIONS
199	A Case of Aortitis with Systemic Lupus Erythematosus. Journal of Rheumatic Diseases, 2015, 22, 205.	1.1	1
200	Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon. Arthritis Research and Therapy, 2015, 17, 77.	3.5	20
201	Drug-loaded gold/iron/gold plasmonic nanoparticles for magnetic targeted chemo-photothermal treatment of rheumatoid arthritis. Biomaterials, 2015, 61, 95-102.	11.4	121
202	Disease duration and Medsger's severity score are associated with significant liver fibrosis in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S68-74.	0.8	5
203	Delta Neutrophil Index as an Early Marker for Differential Diagnosis of Adult-Onset Still's Disease and Sepsis. Yonsei Medical Journal, 2014, 55, 753.	2.2	26
204	Differences in Clinical Manifestations and Outcomes between Adult and Child Patients with Henoch-Schönlein Purpura. Journal of Korean Medical Science, 2014, 29, 198.	2.5	109
205	Usefulness of Serum Leucine-Rich Alpha-2 Glycoprotein as a Disease Activity Biomarker in Patients with Rheumatoid Arthritis. Journal of Korean Medical Science, 2014, 29, 1199.	2.5	37
206	Inhibition of glycogen synthase kinase-3β suppresses inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes and collagen-induced arthritis. Joint Bone Spine, 2014, 81, 240-246.	1.6	29
207	Plasma chemerin levels in rheumatoid arthritis are correlated with disease activity rather than obesity. Joint Bone Spine, 2014, 81, 189-190.	1.6	32
208	Secreted frizzled-related protein 5 suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes through down-regulation of c-Jun N-terminal kinase. Rheumatology, 2014, 53, 1704-1711.	1.9	24
209	Soluble CD93 Levels in Patients with Acute Myocardial Infarction and Its Implication on Clinical Outcome. PLoS ONE, 2014, 9, e96538.	2.5	17
210	Treating rheumatoid arthritis to target: recommendations assessment questionnaire in Korea. Clinical Rheumatology, 2013, 32, 1791-1797.	2.2	3
211	Adjusted neutropenia is associated with early serious infection in systemic lupus erythematosus. Modern Rheumatology, 2013, 23, 509-515.	1.8	4
212	Targeted Chemo-Photothermal Treatments of Rheumatoid Arthritis Using Gold Half-Shell Multifunctional Nanoparticles. ACS Nano, 2013, 7, 50-57.	14.6	217
213	Typical 18-FDG-PET/CT Findings of Polymyalgia Rheumatica: A Case Report. Journal of Rheumatic Diseases, 2013, 20, 113.	1.1	4
214	Adjusted neutropenia is associated with early serious infection in systemic lupus erythematosus. Modern Rheumatology, 2013, 23, 509-515.	1.8	2
215	Multicenter Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. Autoimmune Diseases, 2012, 2012, 1-6.	0.6	18
216	Tuberculin reaction is not attenuated in patients with rheumatoid arthritis living in a region with intermediate burden of tuberculosis. Rheumatology International, 2012, 32, 1421-1424.	3.0	8

#	Article	IF	CITATIONS
217	The role of ¹⁸ Fâ€fluorodeoxyglucose–positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis and Rheumatism, 2012, 64, 866-875.	6.7	88
218	The Effect of Hypouricemic Treatment on the Renal Function in Patients with Gout. Journal of Rheumatic Diseases, 2011, 18, 26.	1.1	1
219	A Case of Ankylosing Spondylitis with Follicular Lymphoma. Journal of Rheumatic Diseases, 2011, 18, 315.	1.1	0
220	ANCA-associated Vasculitis after Scrub Typhus. Infection and Chemotherapy, 2011, 43, 82.	2.3	1
221	Clinical Manifestations of Korean Adult Patients with Henoch-Schönlein Purpura. The Journal of the Korean Rheumatism Association, 2010, 17, 133.	0.1	3
222	The Mid-Range of the Adjusted Level of Ferritin Can Predict the Chronic Course in Patients with Adult Onset Still's Disease. Journal of Rheumatology, 2009, 36, 156-162.	2.0	30
223	Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. American Journal of Medicine, 2002, 113, 188-193.	1.5	163
224	Atherosclerosis in rheumatoid arthritis: Morphologic evidence obtained by carotid ultrasound. Arthritis and Rheumatism, 2002, 46, 1714-1719.	6.7	213
225	Is thyroid autoimmunity a predisposing factor for fibromyalgia? A systematic review and meta-analysis. Clinical and Experimental Rheumatology, 0, , .	0.8	1
226	Serum galectin-9 could be a potential biomarker in assessing the disease activity of antineutrophil cytoplasmic antibody-associated vasculitis. Clinical and Experimental Rheumatology, 0, , .	0.8	1
227	Effect of numbers of metabolic syndrome components on mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis with metabolic syndrome. Clinical and Experimental Rheumatology, 0, , .	0.8	1
228	Application of the 2022 ACR/EULAR criteria for microscopic polyangiitis to patients with previously diagnosed microscopic polyangiitis. Clinical and Experimental Rheumatology, 0, , .	0.8	2
229	Fatty Liver Index Independently Predicts All-Cause Mortality in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis but No Substantial Liver Disease. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3